FDA, CTTI Convening Hybrid Public Workshop on Artificial Intelligence in Drug & Biological Product Development

The Food and Drug Administration (FDA), in collaboration with the Clinical Trials Transformation Initiative (CTTI), is convening a hybrid public workshop on the use of AI in drug and biological product development. Registration is now open for this free hybrid public workshop, which will be held both in person and virtually via Zoom.

Please join us as we discuss guiding principles for the responsible use of AI in the development of safe, effective, and high-quality drugs. Drawing on real case examples, experts will discuss their rationale for particular approaches, share their methods for evaluating success, recount challenges faced, explore options for scaling and wider applicability, and outline considerations for moving forward.

The public workshop is scheduled from 10 a.m. to 5:30 p.m. EDT and is free for all to attend. Participants have the option to attend either virtually or in person at the FDA Great Room, located at 10903 New Hampshire Avenue, Silver Spring, MD 20993.